Novel parameter for cancer chemosensitivity to fibroblast growth factor receptor inhibitors

Fibroblast growth factor receptor inhibitors (FGFRi) were introduced into clinical trials on several cancer types and found to be particularly efficacious on urothelial cancer and cholangiocarcinoma. Although many enrolled patients responded well in clinical trials, there were some patients who did not respond to FGFRi even though their tumors carried the genomic changes that met the enrollment criteria. As already established, fibroblast growth factor receptor (FGFR) and epidermal growth factor receptor (EGFR) share the downstream signaling pathway of MAPK activation. Accordingly, it is conceivable that targeted inhibition of FGFR alone could leave the MAPK signaling unaffected when the signaling through EGFR is relatively strong. To test this hypothesis, we calculated here the FGFR to EGFR mRNA ratio (F/E for short) of biliary tract and urothelial cancer cell lines utilized in preclinical studies. In six biliary tract cancer cell lines, two responsive lines had an F/E of 9.5 and 9.0, whereas the F/E of four nonresponsive lines was 0.1–1.8. In 22 urothelial cancer cell lines, four of the five responsive lines showed an F/E of 2.8–4.9 (median, 3.6), whereas the F/E range of 17 nonresponsive lines was 0.01–2.7 (median, 0.6) (p = 0.004). We further investigated our 47 patient‐derived colorectal cancer‐stem cell spheroid lines. The 18 responsive lines showed relatively high F/E (median, 16.4), whereas 29 nonresponsive lines had low F/E (median, 9.2) (p = 0.0006). These results suggest that F/E is another strong predictor of responses to FGFRi that is as useful as the current genomic criteria based solely on the FGFR genomic changes. Fibroblast growth factor receptor (FGFR) inhibitors were introduced into clinical trials on several cancer types carrying FGFR genomic alterations. However, there were some patients who did not respond to FGFR inhibitors despite that their tumors carried the genomic changes that met the enrollment criteria. Here, we propose a novel parameter that helps predict the chemosensitivity of cancer patients to FGFR inhibitors.